No profile data available.
Kringle Pharma, Inc. (4884.T) is a healthcare company in the brain and nerve treatment drugs industry, based in Kita, Japan, with about 17 full-time employees.
It reported revenue of 72.22 million JPY for fiscal year 2025, down 9.8% from fiscal year 2024, and net income of -916.26 million JPY. Its market capitalization was 5.21 billion JPY as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.
Kringle Pharma reported 72.22 million JPY in revenue for fiscal year 2025, down 9.8% from 80.04 million JPY in fiscal year 2024.
5.21 billion JPY as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include SanBio Company Limited (4592.T), Oncolys BioPharma Inc. (4588.T), K Pharma,Inc. (4896.T), MedRx Co., Ltd (4586.T).